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Abstract
The rates of heroin addiction and opiate overdoses have skyrocketed in America in the last
decade. The government’s response is to expand the availability of Medication Assisted
Treatment (MAT). Because social workers can be expected to be a significant component of the
workforce in providing MAT, MAT is relevant to social workers. Many social workers who are
working in the area of addictions do not hold favorable views of MAT. This paper considers
their objections and evaluates the validity of the basis for these objections. The rationale for the
government’s approach is provided and validity of the rationale for the MAT approach is
evaluated. The “pros” and “cons” of methadone and buprenorphine are reviewed. The paper
distinguishes, beneficial treatment for the individual from the long term impact of a change in
policy on the society.

Key Words: Medication Assisted Treatment, Methadone, Buprenorphine, Opiate Epidemic,
Opiates, heroin
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Expanding Access to Medication Assisted Treatment:
The U.S. Government’s Response to The Current Heroin Epidemic
The Present Epidemic
The rate of illicit drug use has risen precipitously in the US over the last decade.
Seventy-five percent of these new cases have been addicted through prescription drugs such as
OxyContin (Cicero, Ellis, Surratt, & Kurtz, 2014). When prescription drugs such as OxyContin
become too expensive, many patients switch to cheaper street heroin. In addition to opiate
addiction rates increasing, overdoses have also quadrupled from 1999 to 2010. Prescription
opiate drug overdoses in 2010 (at 16651 cases) far exceeded overdoses from street heroin (at
3036 cases) (Volkow, Frieden, Hyde, & Che, 2014).
Along with the increase in the numbers addicted to opiates, the demographics of those
who become addicted to opiates have changed. Heroin addiction is no longer restricted to urban
areas (Cicero et al., 2014). While all demographic groups experienced an increase in heroin use,
the highest increases occurred for females, persons initiating use between ages 18-25, persons
initiating use after age 26, persons earning between $20,000 and $49,999 annually, non-Hispanic
whites, and those with private insurance (CDC, 2015).
A major component of the government’s response to the epidemic is the promotion of
medication assisted treatment (MAT). Medication assisted treatment includes being maintained
on methadone or buprenorphine. Tom Frieden, from the CDC, and Nora Volkow, from the
National Institute of Drug Abuse, have promoted the expansion of methadone and buprenorphine
(Volkow et al., 2014). Michael Botticelli, Director of the White House’s Office of National
Drug Control Policy, is also a strong advocate and spoke at the April 2015 convention of persons
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who operate opioid treatment clinics (American Association for the Treatment of Opioid
Dependence, AATOD) in Atlanta, Georgia. Presently, Drug Courts which fail to offer MAT
options are not eligible for federal funding (Grim & Cherkis, 2015; Knopf, 2015; see also
Substance Abuse and Mental Health Services Administration (SAMSHA), 2015b). SAMSHA
(2012, p. 9), the government agency that regulates MAT, is on record as encouraging the change
in perception of opioid agonist maintenance. We are to call methadone maintenance,
“Medication Assisted Treatment”. According to SAMSHA (2012) “The terms ‘substitution
treatment’ should be avoided because it incorrectly implies that long-acting opioid medication
act like heroin and other short-acting opioids”, p. 9.
SAMSHA’s New Rules
Methadone programs have been operating since the mid-1950s in New York State.
Under the Narcotic Treatment Act of 1974, methadone maintenance clinics became legal in the
United States, although states vary in state regulations. What is new is that SAMSHA has
effectively rewritten the rules on how methadone maintenance clinics are run. Whereas the law
of 1974 limited methadone to those who had been addicted for a year, the SAMSHA (2012, Tip
43; 2015, p. 22) guidelines allow for those who are not physically dependent on opiates to
receive methadone. While initially the goal was to wean patients off, SAMSHA (2012, p. 117)
advises directors of clinics that when a patient requests a dosage reduction that they should
“educate” the patients on the importance of staying on their Medication Assisted Treatment.
There is no duration limit on MAT. Moreover, there is no longer a limit on dosage. Given that
stress is a reliable precipitant to relapse in drug abusers, SAMSHA discusses increasing dosage
during stressful times (see page 77, in SAMSHA’s Tip 43, Medication-Assisted Treatment).
Similar recommendations for not limiting treatment to those who are physically dependent for a

MAT 5

year, no dosage limit, and discouraging discontinuation of buprenorphine are also are found in
SAMSHA’s recommendations for buprenorphine treatment (SAMSHA, 2004).
Relevance of MAT for Social Workers
Social workers will be part of the professional work force employed in methadone clinics
and the professionals providing social services for persons receiving buprenorphine. Social
workers currently comprise a sizable portion of the Substance Abuse treatment workforce
(Roman, Johnson, Ducharme, & Knudsen, 2006). Moreover, NASW offers a specialty credential
in the addictions. Most addiction treatment in the U.S. continues to be dominated by the AA
points of view (Fletcher, 2012) and in a national sample of treatment providers, 45% reported
being in 12 Step recovery (Rieckmann, Kovas, McFarland, & Abraham, 2011). A major tenant
of Alcoholics Anonymous is the promotion of abstinence from mood and mind altering
chemicals. In fact, many social workers and counselors employed in the addictions field,
especially those who are in AA supported recovery, do not approve of “Medication Assisted
Treatment” (Bride, Abraham, Kintzle, & Roman, 2013; Fitzgerald & McCarty, 2009;
Rieckmann et al., 2011). Thus, if the current substance abuse workforce is to be involved in
MAT, many will need to reevaluate MAT.
The purpose of this paper is to consider the rationale for the shift in the federal
government’s policy regarding opiate drugs (viz., methadone and buprenorphine) and the
validity of this rationale. We will examine whether methadone or buprenorphine maintenance
results in compulsive acquisition of these substances. We will consider whether the expansion of
MAT will result in an increase in the number of new opiate addicted persons. The paper ends
with reflections upon the current shifts in SAMSHA’s policies and shifts in the public
perceptions of various drugs which have previously been viewed with opprobrium.
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A Little Background: the Physiology of Opiate Drugs
In explaining and evaluating the changes in the government’s policies regarding the
treatment of drug addiction, a frank look at the physiological consequences of these substances is
required. The effects differ, depending both on the drugs and whether, and how, they are
combined. To help the reader navigate these passages, this section of the paper (the next five
paragraphs), offers background information on the body’s opiate receptors and the drugs that
occupy them. Those familiar with this material can skip directly to the section headed: “What is
Medication Assisted Treatment.”
There are 3 types of opiate receptors in the body: mu receptors, delta receptors, and
kappa receptors. The natural chemicals that bind are, respectively: endorphins, enkephalins, and
dynorphin. Dynorphin, a natural chemical in the body, will counter the effects of activation of
mu receptor and generally produces effects opposing the activity at a mu-receptor (Bruijnzeel,
2009).
Opiate receptors are wide spread throughout the body. They are found in the spinal cord
and in many brain areas as well as on white blood cells and in the neurons in the digestive track.
Opiate drugs come in two forms: agonists drugs that act like an endorphin and antagonist drugs
that block the action of pharmaceutical agonists and natural endorphins. Opiates, which include
opium, heroin, morphine, methadone, fentanyl, OxyContin, and buprenorphine, exert agonist
(turn on effects) activity at the mu-type receptor (Lṻscher, 2012). The predictable effect of
opiate agonist drugs include: a diminution in pain, diminution in distress/anxiety, minor immune
cell suppression, itchiness in the skin (attributable to histamine release from a type of white
blood cell), constipation, pupil contraction, decreased libido and compromised sexual
functioning, suppression of periods, dry mouth, sweating, euphoria/positive mood, an
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enhancement in motivated behavior at low dose but sleep induction at high doses, and blurred
vision (SAMSHA, 2012, p. 34; Seewald, 2013; Shipton, 2005). Opiates can induce nausea and
vomiting but tolerance to these effects builds rapidly (Shipton, 2005). Tolerance also develops
to the sexual function side effects and effects on menstruation (Joseph, 1994; Joseph, Stanclilff,
& Langrod, 2000).
Overdose. Opiates can suppress the activity of neurons in the breathing centers in the
brain stem. Respiratory depression is responsible for drug overdose deaths of many addicts. In a
survey of drug users, 64.6% indicated they had witnessed an overdose and 34.6% had
experienced an overdose (Lagu, Anderson, & Stein, 2006). Naloxone is an opiate antagonist that
will displace heroin, opium, buprenorphine, morphine, methadone from acting on the mureceptor (O’Connor & Fiellin, 2000). Naloxone can rapidly reverse the respiratory depression
induced by an opiate agonist. However, naloxone is gobbled up by the liver faster (with a halflife of 10-30 minutes) than are many opiate agonist drugs. Thus, even when respiratory
depression is reversed by naloxone, after the naloxone is out of the body, considerable heroin
may still be in the body where it will once again induce respiratory depression. It is important to
continue to observe people who have exhibited respiratory depression for hours after their
breathing improves (Schumacher, Basbaum, & Way, 2013). Naloxone can be delivered as a
nasal spray. SAMSHA is recommending the widespread dissemination of “Opioid Overdose
Toolkits” containing naloxone, and instructions (Volkow et al., 2014).
Drug withdrawal. When exposed to continuous opiates, the proteins involved in
countering the impact of opiates on the cell are up-regulated. (Cells will attempt to maintain
homeostasis.) An abrupt withdrawal of the mu-receptor agonist will yield an overactive cell.
Symptoms of opiate drug withdrawal include: nausea, flu like aches, goose bumps, erections in
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males, insomnia, lethargy, and increased blood pressure. Opiate withdrawal is not lethal in a
healthy person, although it is uncomfortable (Lüscher, 2013; Redmond, Kosten, Reiser, 1983;
Tetrault & O’Connor, 2011). Each particular withdrawal symptom is generated by a particular
type of cell that has a receptor (a mu-receptor) for receiving a message from an opiate. For
example, the cells in the Locus Coeruleus produce increased blood pressure and goose bumps
(piloerection) associated with withdrawal, but not the flu like nausea (Mazel-Robison & Nestler,
2012; Nestler, 2004).
What Is Medication Assisted Treatment?
Medicated Assisted Treatment for opiate addiction includes methadone maintenance,
buprenorphine maintenance, and maintenance on long-acting naltrexone. Explanations of these
treatments are provided.
Methadone. Methadone is a synthetic drug which acts as an opioid agonist drug at mureceptors throughout the body. It is administered orally in the form of a syrup. It was
synthesized during World War II when Europe was looking for alternatives to the opium poppy
for pain treatment. Its use as a MAT was pioneered by Vincent Dole and Marie Nyswander in
New York state during the 1950-60s (Joseph et al. 2000; SAMSHA, 2012). Methadone has a
longer duration of activity (24-36 hours) than heroin so that patients only need to dose once per
day in order to forestall withdrawal symptoms in contrast to heroin which requires administration
3 times per day (Joseph et al., 2000; SAMSHA, 2012, p. 28). As a consequence, patients are
able to sustain employment (SAMSHA, 2012, p. 17).
The side effect profile for methadone is common to all opiate drugs, although side effects
are less severe with buprenorphine. Side effects include risk of respiratory depression,
constipation with abdominal pain and bloating, sleep-disordered breathing, vomiting, sedation

MAT 9

(Webster, 2013). As with most opiates, methadone will decrease the body’s production of
estrogen and testosterone (Webster, 2013). Tolerance, over time, to the immune suppressant
effects as well as the effects on sexual function does occur when the drug is administered on a
reliable basis (Joseph, 1994).
In the last 20 years, data has emerged showing that outcomes in Methadone maintenance
are much better when dosages are high (Faggiano, Vigna-Taglianti, Versino, & Lemma, 2003;
Johnson et al., 2000; Joseph et al., 2000; Hartel et al., 1995). In the early days, those who ran
methadone maintenance clinics often did not approve of maintaining patients on a drug (Joseph,
1994). Presently, federal regulations suggest no restriction on the duration of time in treatment,
and federal guidelines prohibit a cap on the level of medication so that positive treatment
outcomes (viz., retaining patients in treatment, avoiding relapse, preventing the emergence of
withdrawal symptoms) can be ensured (SAMSHA, 2015).
In terms of dosage levels, SAMSHA suggests desirable target dosages should abolish
craving and abolish withdrawal symptoms. However, if the patient is overly sedated, then the
dosage should be reduced (SAMSHA, 2012, p. 70-82). Many drugs (e.g., antifungals,
benzodiazepines, SSRIs, antibiotics) compete for the same metabolizing enzyme in the liver
thereby decreasing the rate of elimination (Webster, 2013). Thus, particular drugs can increase
the effectiveness of methadone so that lower doses suffice to achieve the targeted effect.
Conversely, methadone can increase the effective dose of particular HIV medications (McCanceKatz, Sullivan, & Nallani, 2010).
The perception that methadone will not produce a euphoric “high” (Steiker, et al., 2013)
and that it will preclude the capacity for getting high from heroin (Joseph et al., 2000) is
sometimes encountered. According to Dole, Nyswander, & Kreek (1966), methadone is
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supposed to be administered consistently at high enough dosage levels such that tolerance
develops which will preclude euphoria if heroin is taken. This is referred to as a “blockade”. In
the 1966 article, Dole et al. presented data consistent with their hypothesis.
Buprenorphine. Buprenorphine is a derivative of the opium poppy (Papaver
somniferum). Its backbone is similar to the shape of morphine and it has other “side chain”
atoms attached. It will displace other opiate agonists (morphine, heroin) from the mu receptor,
although it will be displaced by naloxone (Cowan, Friderichs, Straβburger, & Raffa, 2005;
Walsh & Middleton, 2013).
Buprenorphine is available as a mono-preparation (Subutex) which comes in the form of
a capsule. Experience suggests that some addicts will remove the capsule’s contents and try to
inject the contents with a hypodermic needle. To prevent this, the pharmaceutical house
(Reckitt-Benckiser) has devised a way to limit injection use. Suboxone contains both naloxone
and buprenorphine. Suboxone is delivered in a form that is placed under the tongue. Only the
buprenorphine is absorbed from the mucus membrane in the mouth. If the tablet is crushed and
injected, the naloxone effect predominates. Thus, the Suboxone preparation precludes high
potency delivery. A new buccal preparation applied to the gums is also available from ReckittBenckiser (Phillips & Preston, 2013). Generic Suboxone pills became available in 2009 and
Zubsolv is approved for use in office-based practice (Johanson, Arfken, di Menza, & Schuster,
2012).
Buprenorphine has been characterized as an antagonist at the opioid kappa receptor and
as a partial agonist at the mu-opioid receptor. The characterization of buprenorphine as a partial
mu-receptor agonist may provide a false impression that buprenorphine in contrast to heroin or
morphine is not really an opiate. In fact, the characterization of a drug in this way is somewhat
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misleading. According to Cowan et al. (2005, p. 18), “it seems inappropriate to describe
buprenorphine with terms such as partial agonist or agonist-antagonist, which in any case are not
very helpful since they are highly test-dependent.” A drug can be a full activator in one type of
tissue whereas it is a partial agonist in other areas of the brain, spinal cord, or other areas of the
body.
A great deal is now known about how receptors for various neurotransmitters operate as
well as where a particular drug binds to and influences a receptor. There are inhibitory proteins,
called regulators of G protein signaling (RGS), which curtail the activity of an opiate drug or
natural chemical at a particular mu receptor. Neurons at various locations differ in whether they
have these RGS proteins associated with their mu receptors. Traynor (2012), who works on
RGS proteins, argues that buprenorphine’s partial agonist impact at the mu receptor may be
because of its unique interaction with RGS. According to Traynor “depending on the level of
RGS protein activity buprenorphine may be seen as a full or partial agonist” (p. 4). It should be
noted that buprenorphine is a full agonist in terms of its impact on some measures of pain
suppression (Cowan et al., 2005, p. 8).
There are several outcomes on which buprenorphine is a partial agonist. In contrast to
other opioid agonists such as heroin or morphine, buprenorphine does exert less activity in the
breathing centers in the brain stem. Thus, respiratory depression and death are less likely to
occur with buprenorphine than with other opiate agonists (Dahan, 2005). However, when used
in combination with alcohol, valium-type drugs (benzodiazepines), or antipsychotics, lethal
overdoses have been reported (Kintz, 2001; McCance-Katz, Sullivan, & Nallani, 2010; Shipton,
2005).
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Another outcome on which buprenorphine appears to be a partial agonist is in the
suppression of particular withdrawal symptoms. If those who are addicted to heroin and using
very high doses substitute buprenorphine for heroin, then withdrawal symptoms will ensue
(Preston, 2005). Transitioning a client from heroin to buprenorphine must be done carefully to
avoid the discomfort of withdrawal.
Various mu-receptor agonist drugs can be compared with each other. With regard to
withdrawal, buprenorphine withdrawal symptoms are minimal (McCance-Katz et al., 2010;
Phillips & Preston, 2013), whereas methadone is associated with more severe and protracted
withdrawal than heroin (Gossop & Strang, 1999). Burprenorphine is associated with lower
levels of constipation than methadone (Shipton, 2005). Buprenorphine can be administered
every other day while methadone requires daily dosing (Leal & January, 2013; Preston, 2005).
Patients prefer buprenorphine to methadone (Phillips & Preston, 2013).
The DATA Waiver. Under the Drug Addiction Treatment Act of 2000 and a 2006
amendment, physicians who have received 8-hours of training are allowed to prescribe
buprenorphine, a schedule III drug, for up to 30 patients during the first year of practice and then
100 patients per year after that. Treatment can be provided in the context of an outpatient
primary practice office. This is referred to as the DATA waiver. If physicians are associated
with an Opioid Treatment Program (OTP) certified by SAMSHA, physicians, who have DEA
authority to prescribe methadone can also dispense buprenorphine for treatment of addiction in
the context of the OTP. Presently, any physician may prescribe methadone (a schedule II drug)
or buprenorphine (a schedule III drug) to treat pain without restrictions on numbers. A physician
associated with an Opioid Treatment Program, can also prescribe methadone for patients seen in
an office setting (Kropf, 2014; SAMSHA, 2012, p. 90). However, only an accredited Opioid
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Treatment Dispenser, i.e., a DEA registered pharmacy, can fill a prescription for methadone
(SAMSHA, 2012, p. 85). On-line, free continuing education and training is available through
Providers’ Clinical Support System sponsored by SAMSHA for physicians prescribing opiates
for treatment of addition (Knopf, 2014).
Naltrexone. Naltrexone is an antagonist at the mu-type opiate receptor which exerts a
longer duration than naloxone. While heroin, methadone, and buprenorphine will bind to an
opiate receptor and induce a change in the neuron, naltrexone will bind to the mu receptor on the
membrane of the neuron but will not have an impact on the neuron. Naltrexone is being used as
a treatment for opiate addiction. Since the purpose of this paper is to consider the rationale for
treatments disapproved of by those in Twelve Step Programs and there is little objection to
naltrexone, it is beyond the scope of this paper to discuss naltrexone. However, it should be
noted that the Cochrane collaboration concluded that naltrexone was, effectively, no better than
placebo, largely because fewer than 20% of patients remain in treatment for longer than 6
months (Bart, 2013; Minozzi, et al., 2011). SAMSHA acknowledges the very poor compliance
with naltrexone treatment (O’Connor & Fiellin, 2000; SAMSHA, 2012, p. 19). The side effects
of naltrexone include anxiety, nervousness, insomnia, headache, joint/muscle pain, and tiredness
(SAMSHA, 2012, p. 35). Additionally, naltrexone can only be started after a client has been
other opiate abstinent for two weeks (SAMSHA, 2004, p. 6). While longer duration injectable
formulations are now available, it is too early to evaluate the efficacy of longer duration
preparations (Bart, 2013).
The Rationale for Treating Opiate Addiction with Another Opiate
The major rationale for medication assisted treatment largely rests on harm reduction
arguments. Illicit opiate addiction creates a great deal of harm in American society. Injection
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drug use does account for 1/3 of HIV cases in the United State and for many cases of infection
with Hepatitis C. In fact, between 60-90% of those who have injected drugs are positive for
hepatitis C virus (HCV) (SAMSHA, 2012, p. 7). Opiate use accounts for 1/3 of the money spent
in the Criminal Justice System (SAMSHA, 2012). As discussed earlier, the number of opiate
drug overdoses has risen sharply. Studies suggest that when MAT (methadone) programs
provide adequate doses (about 100 mg/day), patients are retained in treatment (Mattick, Breen,
Kimber, & Davoli, 2009); involvement in the criminal justice system declines so the government
saves money (Joseph et al., 2000; Lind, Chen, Weatherburn, & Mattick, 2005); heroin relapses
decline (Johnson et al., 2000; Mattick et al.,2009); new infections with HIV decline (Gowing,
Farrell, Bornemann, & Ali, 2004; Metzger, Navaline, & Woody, 1998); patients are more
compliant with HIV medication schedules (Malta, Strathdee, Magnanini, Bastos, 2008; Spire,
Lucas, & Carrieri, 2007); and many return to productive employment (Appel et al., 2001; Joseph
et al., 2000). Intermittent heroin suppresses the immune system while stable methadone or
buprenorphine doses do not have this effect (Sacerdote et al., 2008). (Immune system
suppression is a particular problem for those who infected with HIV or Hepatitis C.) Similar
findings of efficacy are found for buprenorphine as for methadone (Mattick, Kimber, Breen, &
Davoil, 2008; McKeganey, Russell, Cockayne, 2013). These findings constitute the evidence
base for the efficacy of Medication Assisted Treatment.
Heroin is a very dangerous drug. Heroin overdose was the leading cause of death in a
cohort group of the addicted followed for 33 years by Smyth, Hoffman, Fan, & Hser (2007), with
8% of the cohort dying by overdose at a much younger age (late 20s and 30s) than from other
causes of death. Long term studies of the opiate addicted followed out 20-33 years does confirm
the high rate of death at an early age due to risky behavior and overdose (Hser, Anglin, &
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Powers, 1993; Vaillant, 1973). Cohort studies and comparisons of overdose death before and
after expansion of MAT suggest that overdoses decline with MAT (Brugal et al., 2005;
Langendam, van Brussel, Coutinho, & van Ameijden, 2001; Schwartz et al., 2013), although
buprenorphine is more effective than methadone on decreasing overdose deaths (Schwartz et al.,
2013).
In the U.S., opiate agonist treatments are limited to methadone and buprenorphine. In
Europe, some Medication Assisted Treatment programs provide long-acting morphine or heroin
(Strang, Groshkova, & Metrebian, 2012). Europeans view provision of a patient’s drug of choice
as treatment. Reduced-harm outcomes, similar to those observed with methadone and
buprenorphine maintenance, are observed when addicts are supplied with heroin in a structured
manner from treatment centers (Strang et al., 2012).
Assumption that addicts cannot achieve a stable life without some type of opiate.
Vincent Dole and Maire Nyswander, pioneers in the development of methadone maintenance
clinics, argued that exposure to opiate drugs permanently altered the addict’s body in such a way
that abstention was no longer possible (Dole, 1988). The only way to normalize physiology and
return an addict to productive citizenship was provision of a drug that could continuously
stimulate mu-receptors. SAMSHA seems to have accepted a similar assumption with regard to
continuous opioid agonist treatment. SAMSHA’s (2012, p. 117) recommends discouraging
those who wish to pursue withdrawal from MAT. Citing Magura and Rosenblum (2001; see
Joseph 1994, for similar citations) that 80% of those who leave MAT treatment relapse within a
year of treatment termination, SAMHA’s goal is to retain clients (SAMSHA, 2012, p. 78). With
regard to a client’s request to lower a dosage, SAMSHA (2012, p. 78) recommends “These
situations require physicians or other staff members to educate patients and their significant
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others about the importance of adequate dosage and how individual differences in absorption,
body weight, metabolism, and tolerance can affect the dosage necessary to achieve stability.”
Can sobriety ever be achieved? There are data both “for” and “against” Dole and
Nyswander’s assumption that heroin addicts can never achieve sustained sobriety. Data from
soldiers returning from Viet Nam, present a contrasting version to Dole and Nyswander’s
prediction. Forty-five percent of all soldiers returning from Viet Nam had used heroin, and 20%
of those who had used it became addicted. After returning to the United States only fifty percent
of those addicted in Viet Nam tried opiates in the States, with 12% having short period of stateside addiction and only 5% continuing to be addicted during the three year follow-up interval
(Robins, 1993).
In addition to the data from the Viet Nam veterans, several studies of a California cohort
speak to the possibility of long term abstinence in those who were at one point addicted to
heroin. Hser et al. (1993) conducted a study with a sample size of 581 addicts from the
California criminal justice system, only 10% of whom were engaged in methadone maintenance.
They found that years later, if death at an early age was avoided, sizable percentages did not test
positive for opioids. The numbers were as follows: 37.8% interviewed at 10 years out and 41%
interviewed at 20 years out did not test positive for opiates; at 20 years out, 18.9% of Hser et al.
sample had been opioid abstinent for at least three years. In a subsequent 33 year follow-up of
the same sample, 79.3% were negative for heroin and 46.7% had been abstinent for more than 5
years. On the other hand, even after 15 years of abstention, ¼ of opiate addicts did relapse
(Hser, Hoffman, Grella, & Anglin, 2001).
Many of the recent longitudinal studies addressing long term outcomes of opiate addicts
fail to distinguish whether clients are in methadone programs and thus the data are not relevant to
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evaluating probability of sobriety without treatment. However, an early study conducted when
methadone maintenance was less available found that 21.6% who were living in the community,
were not using narcotics at the 20 year follow-up (Nurco, Bonito, Lerner, & Balter, 1975). Of
those who elected to leave methadone treatment in an early Dole and Nyswander study, 34%
were doing well without criminal or drug involvement at two-year follow-up (Joseph et al.,
2000). Thus, there is considerable variability in the “natural course” of the disease.
An early rationale for methadone proffered by Dole and Nyswander was that opiates
change the brain (Dole, 1988). Similar arguments regarding chemicals changing the brain are
made for other chemicals of abuse. For the most part, the addiction literature suggests that the
same brain changes are common to all drugs of abuse (Nestler, Hyman, & Malenka, 2009;
Sankey, Dobrin, & Roberts, 2011; Sankey & Nestler, 2011; Volkow & Li, 2011). If this is the
case, we can look to rates of sobriety for alcoholics and stimulant abusers. If they do not die,
many alcoholics do achieve meaningful sobriety (Vaillant, 1995). The logic then supports the
expectation of eventual sobriety for some opiate addicts. Some explanation of why the brain
changes induced by opiate use is so much more extreme than brain changes induced by other
drugs needs to be advanced before dismal outcomes are assumed to be “just part of the disease”.
Consistent with the possibility of more severe brain changes induced by opiates as
opposed to other drugs of abuse, short term recovery rates for those who abuse opioids are lower
than for those who abuse stimulants and less than 5% of heroin addicts seek treatment
voluntarily (Hser et al., 1993; Hser, Evans, Huang, Brecht, & Li, 2008). This might reflect more
severe brain changes in those abusing opioids than those who abuse other drugs (viz., alcohol
and cocaine). It is also possible that these rates may reflect the differences of various drugs in
the physical effects on the body. Heavy drinking and cocaine are very punishing on the body
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both in the long and short term. In contrast, opiates derived from the poppy family, when not
associated with use of unsterile injection methods and when associated with a reliable access so
withdrawal is avoided, produce limited damage on the body (DaSilva & Hazar, 2011; Friedman,
2011; Haber & Batey, 2011; Kwasnicka & Haber 2011). Moreover, as attested to by the
favorable employment patterns of many persons in MAT, and the fact that motor vehicle
problems are not elevated in MAT patients, opiates, when consumed on a routine basis, exert
little impairment of function (Joseph et al., 2000). Unlike other drugs of abuse (viz., alcohol and
stimulants), opioids have fewer inherent downsides on the body.
Can findings from drug-addicted cohorts of earlier times be extrapolated to the new
population of addicts? In contrast to the rather limited recovery rates for heroin addicts from
older studies, Magura (2009) raises the question of whether these findings can be generalized to
prescription opioid abusers, a new population of persons addicted to opiates. It should be noted
that the new addicts can also include seniors. Compton and Volkow (2006) also state, “Most of
what we know about opioid abuse and addiction has been learned from heroin addiction in 20 to
40 year old individuals”, p. 104. Thus, whether the current new population of addicts will be
more similar to addicts who returned from Viet Nam, the addicts who initiated their addiction
with street heroin, or different from both, is unclear. McKeganey et al. (2013) present findings
suggesting that those in MAT remain dependent on opioids for a longer period than do those who
are not involved with MAT. Magura, similar to the McKegancy et al. (2013), questions whether
participation in methadone maintenance will further solidify the drug dependence of prescription
opioid abusers.
A Closer Look at Why People in Twelve Step Recovery Object to Methadone and
Buprenorphine
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People in Twelve Step programs pursue freedom from all mood and mind altering
chemicals. The assumption is that using one addictive chemical will undermine abstinence from
one’s drug of choice.

SAMSHA (2012) suggests that “The terms ‘substitution treatment’

should be avoided because it incorrectly implies that long-acting opioid medication act like
heroin and other short-acting opioids”, p. 9. In this section, we’ll consider whether
buprenorphine and methadone are different from other opiates. We will consider whether
medication assisted treatment results in addiction defined as compulsive pursuit of chemicals.
Issue of Addiction. The concept of addiction has changed considerably in recent times.
At an earlier point, addiction was defined as physical dependence on a chemical. Particular
drugs that are taken continuously but then discontinued abruptly can result in the emergence of
very troublesome symptoms (withdrawal symptoms). However, with the realization that many
drugs (lithium, antipsychotics, antidepressants) are associated with withdrawal symptoms but do
not lead to compulsive use has led to the abandonment of physical dependence as the core
feature of addiction (Nestler, 2004; Nestler, Hyman, & Malenka, 2011; Sankey & Nestler, 2011).
As discussed previously, methadone and buprenorphine are associated with withdrawal
phenomena. However, withdrawal phenomena are no longer considered the defining feature of
addiction.
Neuroscientists such as Eric Nestler, Peter Kalivas, Marina Wolf emphasize compulsive
drug seeking as a more accurate defining characteristic of addiction (Everitt & Wolf, 2002;
Kalivas & Volkow, 2005; Nestler, 2004; Sankey & Nestler, 2011; Wolf, 2002). A current view
of addiction is that the drug has captured the brain’s motivational system. An addicted person
works for the drug, because the individual’s motivational system is a hostage to the drug (Dong
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& Nestler, 2014; Nestler, 2004). This characterization comports well with Twelve Step
representation of addiction: there is a loss of control and volition (choice) is no longer relevant.
Animal research on addictive drugs suggests the way a chemical is administered can
determine whether the same chemical (for example cocaine or amphetamine) results in
compulsive drug seeking. When drugs are administered on a regular routine basis, rather than
intermittently, in the animal’s home cage, compulsive-drug seeking does not occur (Caprioli et
al., 2007; Robinson & Berridge, 1993). Coming daily to the methadone clinic and receiving
methadone at the same time in a highly familiar setting may capture the extant prevailing
conditions for the animals who fail to develop a compulsive use pattern. Thus, methadone and
buprenorphine administered under routine conditions may indeed fail to produce the compulsive
behaviors which constitute the essential features of addiction.
Opiates Are Not Safe Drugs
The evidence suggests that MAT will decrease the risk of opiate over-dose death for
those who can’t achieve sobriety. However, methadone and buprenorphine carry their own
risks. As mentioned previously opiates can induce respiratory depression. The rates are 0.05%
for morphine, 4.0% for methadone, and none for buprenorphine (Shipton, 2005). Not only are
opiates associated with respiratory depression, but methadone (but not heroin) is associated with
cardiac arrhythmias (Barceloux, 2012). The rate for methadone is 0.78% for torsades de pointes,
a severe form of cardiac arrhythmia, and 0.29% for another indicator, QT wave prolongation
(Leal & January, 2013; Preston, 2005; Seewald, 2013). Some antipsychotics and antidepressants
are also associated with QTc prolongation, compete for the same enzyme for metabolism as
buprenorphine or methadone, and thus potentiate the risk of sudden death (Beach et al., 2014;
Haddad & Anderson, 2002; McCance-Katz et al., 2010). In terms of opiate medication
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overdoses, 22% are associated with simultaneous use of alcohol (SAMSHA, 2015, p. 37) and
alcohol makes buprenorphine an unsafe drug (Kintz, 2002). Studies of sudden death in those
receiving prescription opiates suggests that concurrent use of opiates with antidepressants,
antipsychotics, alcohol, and benzodiazepines potentiates risk (Kintz, 2001; Leece et al., 2015;
Zedler et al., 2014; 2015).
Risk potentiation attributable to concurrent use of other chemicals with buprenorphine or
methadone is particularly relevant for addicts entering MAT. According to the CDC, the new
population of heroin addicts are often poly drug abusers (CDC, 2015).

According to Joseph et

al. (2000) approximately 20% of those entering methadone programs have extant alcohol
problems. In Dole and Nyswander’s original sample, 80% of those who were drinking heavily
prior to methadone treatment continued to do so during methadone treatment (Joseph et al.,
2000). A recent study by Cone (2012) found the about half of methadone clients were
supplementing with other drugs. SAMSHA (2012) generally discourages dis-enrolling anyone
from methadone maintenance for any reason (p. 179; p. 186) and SAMHSA suggests that urines
containing evidence of illicit drug use be called “positive urines” rather than “dirty urines”
(SAMSHA, 2012, p. 9).
In terms of limiting the danger for those MAT clients who abuse other drugs, onsite
administration of methadone and buprenorphine can be required. The guidelines for
buprenorphine specify that clients who abuse or are dependent on alcohol or sedative-hypnotics
are not appropriate for office-based treatment (SAMSHA, 2004, p. 42). If overdose deaths of
those in MAT are to be avoided, additional effective strategies for ensuring that MAT clients
curtail use of other chemicals will need to be in place.

MAT 22

Will the Expansion of MAT Increase the Number of Addicts and Opiate Overdoses in
America?
The federal government is committed to expanding the availability of opiate treatment in
the U.S. Basically, the current heroin epidemic was initiated by increased availability of opiates
initiated by a change in the way medicine was practiced. The journalist, Sam Quinones (2014),
tells the story of how the pharmaceutical houses promoted the idea that if a patient was in pain,
that patient could not be addicted to an opiate. Key opinion leaders were paid to present the
“evidence-base” at continuing education events. The FDA bought the argument that OxyContin,
because of its timed released preparation, had little addictive liability. Sales representatives
offered coupons to doctors which could be redeemed at pharmacies for free OxyContin. More
physicians began assessing for pain and writing prescriptions (Compton & Volkow, 2006; Dhalla
et al., 2009; Olsen, Daumit, & Ford, 2006) even for young people (Fortuna, Robbins, Caiola,
Joynt, & Halterman, 2010). With more opiates in the family medicine chest, the family medicine
chest became the gateway to opiate abuse for young people (Fortuna et al., 2010). Eventually,
the downsides to this change in policy appeared. Report of an increase in opiate related
overdoses in those filing claims with Workmen’s Compensation was noted (Franklin et al.,
2005), as well as an increased number of deaths and emergency room visits in the general
population (Compton & Volkow, 2006; Dhalla et al., 2009). In 2007, the makers of OxyContin
pled guilty to charges of deceptive marketing (Dhalla et al., 2009; Meier, 2007).
With the expansion of Medicated Assisted Treatment, there will be more methadone and
buprenorphine in the general population. There are street markets for both methadone and
buprenorphine (Clark, & Baxter, 2013; Duffy & Baldwin, 2012). Deborah Sontag (2013), in the
New York Times, discusses the unscrupulous doctors who have established buprenorphine clinics
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where they indiscriminately prescribe similar to the way in which OxyContin clinics increased
the sales of OxyContin (as told by Sam Quinones, 2014). Surveys of knowledgeable individuals
suggest that the supply of street buprenorphine comes from persons with legitimate prescriptions
(Clark & Baxter, 2013; Johanson et al., 2009). From 2005 to 2010, emergency room visits for
buprenorphine increased by a factor of 10, half of which involved non-medical use of
buprenorphine (Clark & Baxter, 2013). With increased availability, more young people will be
tempted toward casual use of chemicals which the federal government calls “medication”.
Consistent with the concern that MAT will expand the number of people using
prescription opiates, McKeganey et al. (2013) report that the overdoses from methadone exceed
overdoses from heroin in some areas in Scotland. According to McKeganey et al. (2013), the
health care system in the UK is now more focused on helping people move toward abstinence
and continues to label methadone as opioid substitution. Methadone overdoses have also
increased substantially since 2000 in the United States and throughout the world (Madden &
Shapiro, 2011).
Bottom-lines: the evidence for MAT. A strong case can be made that engagement in
MAT does allow people to return to better functioning and will decrease the risk of accidental
death for the individual. As MAT expands, it will be important to monitor whether the number
of addicts increases and, because the size of the pool of opiate using persons has increased,
whether there will be an increase in the number of opiate deaths. Thus, while MAT may be the
best “evidence-based” treatment for the individual, the impact of expansion of MAT on society
may be another story.
Ambiguities
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SAMSHA’s recent policies reflect a major shift in strategies for dealing with addiction.
As discussed previously, SAMSHA recommends including the severely addicted as well as the
less severely addicted for MAT, and abstinence should be discouraged. Attitudes toward a broad
range of drugs are changing in American society generally. Medical marijuana is legal in 23
states plus the District of Columbia and four states allow recreational use. Methamphetamine
and cocaine are schedule II drugs, but 11% of children are diagnosed with ADHD and 6.1% of
American children receive medications, primarily stimulants for ADHD (CDC, 2014). In fact, at
a Brains and Behavior lecture presented by philosopher Nicole Vincent (2014) at Georgia State,
she promoted the idea that Ritalin use should be required for physicians in practice because it
improves performance. As attitudes and laws are changing, the need for some rational basis for
deciding those behaviors we wish to encourage or discourage is sorely needed. Many persons in
Twelve Step supported recovery are totally opposed to methadone and would not include
maintaining physical dependence on an opiate under any definition of recovery. In Europe, some
Medication Assisted Treatment Programs provide long-acting morphine or heroin (Strang et. al.,
2012). Apparently, Europeans view provision of a patient’s drug of choice as treatment.
Buprenorphine is in clinical trials for treatment resistant depression (Clinical Trials, 2014; Fava
et al., 2016), so the society may soon have to decide whether buprenorphine for the 9.5% of
those meeting criteria for depression is acceptable (Kessler, et al., 2005). Opinions vary
dramatically. Hopefully this essay will spur discussion so that a consensus on rational policy
toward experience-altering substances can be reached.
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